Colchicine after Electrocardioversion for Atrial Fibrillation - The COLECTRO-AF Trial

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516033-12-00

Enrollment

Registered

2026-06-26

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Brief summary

Documented AF recurrences within 6 months after ECV in patients with AF.

Detailed description

Documented AF recurrences within 1 month after ECV, Documented AF recurrences within 3 months after ECV, Time to first redo ECV, Use of anti-arrhythmic drugs (Vaughan Williams class 1 or 3) at 6 months, Survival free of unplanned hospitalization

Interventions

DRUGPlacebo Colchicine 0.5 mg tablets are cream-white

DRUGcircular tablets

DRUGwith a diameter of 6 mm

DRUGthickness of 3 mm

DRUGwith “0

DRUG5” engraved on one side. With the exception of the active ingredient (Colchicine) for the placebo IMP

DRUGthe components of the active and placebo tablets are identical (see Table 1 on page 9 in IMPD for more info).

DRUGColctab 0

DRUG5 mg Tabletten

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Documented AF recurrences within 6 months after ECV in patients with AF.	—

Secondary

Measure	Time frame
Documented AF recurrences within 1 month after ECV, Documented AF recurrences within 3 months after ECV, Time to first redo ECV, Use of anti-arrhythmic drugs (Vaughan Williams class 1 or 3) at 6 months, Survival free of unplanned hospitalization	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 27, 2026